# JANUARY 2022

Does early treatment with highly effective DMT improve prognosis for people with MS?

HAPPY NEW YEAR FROM THE DELIVER-MS TEAM!

Welcome to the Jan 2022 edition of the DELIVER-MS newsletter. We are very hopeful that this is the year we will complete enrolment to this important study - but only **YOU** can make that happen! We continue to encourage sites to prioritise recruitment to the randomised study, but to aim for 1-2 enrolments per month overall.

TOTAL ENROLMENT

307

268

72%

MONTHLY ENROLLMENT AS OF 10TH JAN

<u>2+ participants</u>
- Colorado (2)
- VCU (2)

<u>1 participant</u>
- Buffalo
- Cardiff
- Las Vegas
- Ohio Health
- Swansea

<u>0 participants</u>

Can you make it a New Year resolution?

NEWS AND UPDATES

- We have recently welcomed new sites VCU and UT Austin. We are delighted to see that VCU have really aced enrolment so far (thanks Myla) and we look forward to seeing UT Austin's first recruit soon.

- Las Vegas reached n=30 this month and Colorado, Swansea and Baylor are hot on their heels to reach this amazing target.

- It was great to see so many DELIVER-MS investigators at the UK Cutting Edge Science in MS meeting in Dec 21. Focusing on the most controversial aspects of contemporary MS care, the meeting demonstrated that the optimal DMT algorithm is still highly debated.

FINAL THOUGHTS: Let's get Deliver-MS done!!

It would be great if 2022 could be the year that we complete recruitment to DELIVER-MS. We are sure you agree that equipoise continues to be present in our DMT decisions, and you can help produce the data that will guide our algorithms for the coming years.